Apnimed to Present at Oppenheimer’s Private Life Sciences Company Call Series

About Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 25 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway closure that occurs during sleep, which often leads to poor sleep, and in the long-term, hypertension, diabetes, cardiovascular disease, strokes, and early mortality. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but fewer than half are compliant long-term, leaving a significant population untreated and at risk.

About Apnimed

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication. Apnimed’s lead development program targets nighttime neurotransmitter levels in the central nervous system to activate upper airway muscles and maintain an open airway during sleep. The drug is delivered as a convenient once-a-day dose before bed. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at Apnimed.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005668/en/